Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sedation and hemodynamic effects of dexmedetomidine, ketamine, etomidate, and propofol during phacoemulsification cataract surgery
IRCT20141209020258N156Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine, ketamine, etomidate and propofol in cataract (4 arms), sponsored by Arak University of Medical Sciences. Primary endpoints: Sedation level and Hemodynamic changes. Started May 2021; status: completed.
02
Drugs
dexmedetomidineketamineetomidatepropofol
03
Conditions
cataract
Beyond the preview
Go deeper on IRCT20141209020258N156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N156.